Gavreto approved for metastatic lung cancer with RET gene fusions Blueprint Medicines’ Gavreto (pralsetinib capsules) has been granted accelerated approval for treating adults with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback